Overall, 953 men were prescreened for AR-V7 323 (34%) had detectable CTCs, and 73/323 had AR-V7 mRNA. Baseline AR-V7 status was correlated with patient characteristics. The primary endpoint was radiographic progression-free survival (rPFS). Outcome measurements and statistical analysis: This was a multicenter randomized phase 3 trial enzalutamide-, abiraterone-, and chemotherapy-naïve mCRPC patients had AR-V7 prescreening using a CTC-based mRNA assay.ĪR-V7+ patients were randomized (1:1) to open-label galeterone or enzalutamide planned sample size was 148. To screen and characterize AR-V7+ mCRPC, and evaluate galeterone compared with enzalutamide. ![]() We hypothesized that galeterone would be clinically superior to enzalutamide in AR-V7-positive (AR-V7+) mCRPC. ![]() Galeterone inhibits CYP17 and AR, and induces AR protein degradation. Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA (mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |